Breaking News Instant updates and real-time market news.

RHHBY

Roche

$28.05

-0.27 (-0.95%)

, EXEL

Exelixis

$21.09

-1.01 (-4.57%)

14:32
04/09/18
04/09
14:32
04/09/18
14:32

Roche study of biomarker-driven therapy in mCRC suspended

A study of biomarker-driven therapy in metastatic colorectal cancer, or mCRC, sponsored by Hoffmann-La Roche (RHHBY) has been suspended "following iDMC review of cohort 4 data a temporary recruitment halt to the whole study and a temporary halt to randomisation into cohort 4 has been undertaken," according to a post to ClinicalTrials.gov. The post is being attributed as the reason for a late day move lower in shares of Exelixis (EXEL), which has dropped over 2%. In January of this year, Exelixis announced the presentation of updated results from the Genentech-sponsored phase 1b clinical trial of cobimetinib, an Exelixis-discovered MEK inhibitor, in combination with atezolizumab, an anti-PDL1 antibody discovered and developed by Genentech, a member of the Roche Group, in patients with metastatic colorectal cancer. Reference Link

RHHBY

Roche

$28.05

-0.27 (-0.95%)

EXEL

Exelixis

$21.09

-1.01 (-4.57%)

  • 08

    May

  • 30

    May

  • 12

    Jun

RHHBY Roche
$28.05

-0.27 (-0.95%)

02/27/18
02/27/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Stryker (SYK) upgraded to Neutral from Sell at Citi by analyst Amit Hazan, who believes supply issues at Zimmer Biomet (ZBH) could drive share gains for Stryker. 2. Chipotle (CMG) upgraded to Outperform from Neutral at Baird by analyst David Tarantino, who cited its new CEO and the potential for the company to demonstrate better sales/traffic momentum over the next 12-24 months. He believes it will support investor sentiment given the opportunity for the company to deliver strong earnings power if unit volumes begin to recover. 3. Itron (ITRI) upgraded to Buy from Hold at Cannacord Genuity by analyst Chip Moore, who said he has increased conviction in the company's forward earnings power and finds current share levels a "very compelling" entry point. He notes the stock is down 10% since the SilverSpring Networks deal announcement back in September. Moore's views the combination as compelling and has increased confidence in cost saving potential post close. 4. Winnebago (WGO) upgraded to Outperform from Market Perform at BMO Capital by analyst Gerrick Johnson, who said that the RV market growth -- currently in its 9th year -- will continue at a 10% pace, adding that the company's growth can outgain the competition because of its "operating improvement, enhanced product offering, and emerging trade-up cycle from first time buyers." The analyst also noted that Winnebago will benefit from lower corporate taxes while its stock trades at "significant" valuation discount. 5. Exelixis (EXEL) upgraded to Outperform from Perform at Oppenheimer by analyst Leah Rush Cann. The analyst is now applying a valuation methodology for profitable companies to Exelixis, since the company turned profitable for the full-year 2017. She expects Exelixis will continue to develop its commercial drugs, Cabometyx and Cometriq, while its partner Genentech (RHHBY) will continue to develop Cotellic. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/09/18
PIPR
03/09/18
NO CHANGE
Target $170
PIPR
Overweight
Piper confident in Alexion positioning after Roche trial halt
Piper Jaffray analyst Christopher Raymond keeps an Overweight on Alexion Pharmaceuticals (ALXN) following news of a temporary trial halt for Roche's (RHHBY) Soliris/AXLN1210 challenger RO7112689 in Europe. While a bit early to write off RO7112689 as a competitive threat, the halt highlights the strength of the clinical profile for ALXN1210 and Soliris, Raymond tells investors in a research note. He remains remains confident in Alexion's positioning and bullish on the shares with a $170 price target.
03/27/18
MSCO
03/27/18
DOWNGRADE
MSCO
Underweight
Roche downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Vincent Meunier downgraded Roche to Underweight from Equal Weight, citing the expected impact of biosimilars on margins and increasing competition in lung cancer. The analyst lowered his 2020 sales and earnings estimates and said Roche offers slower growth in terms of both the top and bottom line over 2018-2021 than large pharma peers. He cut his price target on Roche shares to CHF230 from CHF260.
04/09/18
JEFF
04/09/18
NO CHANGE
JEFF
Buy
Jefferies ponders other potential suitors for AveXis after Novartis deal
Jefferies analyst Biren Amin asks who else can jump into the mix after AveXis (AVXS) agreed to be acquired by Novartis (NVS) for $218 per share in an all-cash deal. The analyst, who does not expect anti-trust issues to arise with the deal on the table, notes the speculation that Biogen (BIIB) may need to evaluate AveXis at some point. The Novartis deal could be the "trigger that forces it to do so," Amin writes in a research note. Further, the analyst has always felt Roche (RHHBY) could have an interest in AveXis given its development program with RG7916. He points out that AveXis Chairman Dan Welch was the CEO of Intermune when Roche purchased the company in 2014 for $8.3B. AveXis in premarket trading is up 81%, or $94.14, to $210.05.
EXEL Exelixis
$21.09

-1.01 (-4.57%)

01/04/18
PIPR
01/04/18
NO CHANGE
Target $37
PIPR
Overweight
Piper ups Exelixis target to $37, names a top pick for 2018
Piper Jaffray analyst Edward Tenthoff names Exelixis a top pick for 2018 and raised his price target for the shares to $37 from $33. The analyst expects Cabometyx growth from driven label expansion and is positive into the Phase III Cotexo data in the first half of 2018.
02/27/18
OPCO
02/27/18
UPGRADE
OPCO
Outperform
Exelixis upgraded to Outperform from Perform at Oppenheimer
02/27/18
OPCO
02/27/18
UPGRADE
Target $40
OPCO
Outperform
Exelixis upgraded to Outperform with $40 target at Oppenheimer
Oppenheimer analyst Leah Rush Cann upgraded Exelixis to Outperform from Perform with a $40 price target. The analyst is now applying a valuation methodology for profitable companies to Exelixis, since the company turned profitable for the full-year 2017. She expects Exelixis will continue to develop its commercial drugs, Cabometyx and Cometriq, while its partner Genentech will continue to develop Cotellic. Cann views the company's Q4 results as "strong."

TODAY'S FREE FLY STORIES

ABBV

AbbVie

$88.28

0.06 (0.07%)

05:29
11/15/18
11/15
05:29
11/15/18
05:29
Hot Stocks
AbbVie signs DUBs collaboration with Mission Therapeutics »

Mission Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNK

Teekay Tankers

$1.07

0.025 (2.39%)

05:26
11/15/18
11/15
05:26
11/15/18
05:26
Earnings
Teekay Tankers reports Q3 adj. EPS (7c), consensus (10c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

ATUS

Altice USA

$17.71

-0.1 (-0.56%)

05:25
11/15/18
11/15
05:25
11/15/18
05:25
Initiation
Altice USA initiated  »

Altice USA initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGP

Teekay LNG

$14.41

0.29 (2.05%)

05:23
11/15/18
11/15
05:23
11/15/18
05:23
Earnings
Teekay LNG reports Q3 adj. EPS 16c, consensus 34c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

SUBCY

Subsea 7

$0.00

(0.00%)

05:22
11/15/18
11/15
05:22
11/15/18
05:22
Upgrade
Subsea 7 rating change  »

Subsea 7 upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EXEL

Exelixis

$16.75

0.09 (0.54%)

, IPSEY

Ipsen

$0.00

(0.00%)

05:20
11/15/18
11/15
05:20
11/15/18
05:20
Hot Stocks
Exelixis receives EC approval for Cabometyx tablets »

Exelixis (EXEL) announced…

EXEL

Exelixis

$16.75

0.09 (0.54%)

IPSEY

Ipsen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 27

    Nov

  • 14

    Jan

CTTAY

Continental AG

$0.00

(0.00%)

05:19
11/15/18
11/15
05:19
11/15/18
05:19
Downgrade
Continental AG rating change  »

Continental AG downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

VLEEY

Valeo

$0.00

(0.00%)

05:18
11/15/18
11/15
05:18
11/15/18
05:18
Downgrade
Valeo rating change  »

Valeo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,599.16

-32.52 (-1.99%)

05:14
11/15/18
11/15
05:14
11/15/18
05:14
Recommendations
Amazon.com analyst commentary  »

Amazon shares offer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 04

    Dec

ATNX

Athenex

$10.28

-1.38 (-11.84%)

05:08
11/15/18
11/15
05:08
11/15/18
05:08
Upgrade
Athenex rating change  »

Athenex upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

STIM

Neuronetics

$18.58

-3.17 (-14.57%)

05:08
11/15/18
11/15
05:08
11/15/18
05:08
Recommendations
Neuronetics analyst commentary  »

Neuronetics selloff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVID

Avid

$5.79

0.19 (3.39%)

04:59
11/15/18
11/15
04:59
11/15/18
04:59
Recommendations
Avid analyst commentary  »

Avid price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIN

Linde plc

$153.45

-3.35 (-2.14%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Initiation
Linde plc initiated  »

Linde plc initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKTX

MarketAxess

$209.85

2.02 (0.97%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
MarketAxess management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

04:55
11/15/18
11/15
04:55
11/15/18
04:55
General news
Breaking General news story  »

Minneapolis Federal…

04:55
11/15/18
11/15
04:55
11/15/18
04:55
General news
Breaking General news story  »

Week of 11/9 EIA Natural…

QLYS

Qualys

$71.92

-0.09 (-0.12%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
Qualys to hold analyst and investor day »

Analyst and Investor Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 09

    Jan

PFG

Principal Financial

$48.29

-0.71 (-1.45%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
Principal Financial to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 03

    Dec

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
RBC Capital telecom/data centers analyst to hold a group luncheon »

Telecom & Data…

CNHI

CNH Industrial

$9.81

-0.03 (-0.30%)

, HSY

Hershey

$107.94

-1.24 (-1.14%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
BlackLine to hold a summit »

In The Black 2018:…

CNHI

CNH Industrial

$9.81

-0.03 (-0.30%)

HSY

Hershey

$107.94

-1.24 (-1.14%)

TAP

Molson Coors

$64.75

0.24 (0.37%)

ZEN

Zendesk

$53.12

0.56 (1.07%)

ETP

Energy Transfer Partners

$0.00

(0.00%)

G

Genpact

$29.11

-0.73 (-2.45%)

SAP

SAP

$103.86

0.11 (0.11%)

BL

BlackLine

$38.78

-1.79 (-4.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 26

    Nov

  • 02

    Dec

  • 06

    Dec

  • 06

    Dec

  • 12

    Dec

  • 13

    Dec

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
RBC Capital software analysts to hold a group luncheon »

Software Analysts Hedberg…

MGM

MGM Resorts

$25.94

0.2 (0.78%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
MGM Resorts management to meet with UBS »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 19

    Nov

AWI

Armstrong World

$66.00

-1.94 (-2.86%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
Armstrong World management to meet with SunTrust »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 16

    Nov

SIRI

Sirius XM

$6.25

0.1 (1.63%)

04:55
11/15/18
11/15
04:55
11/15/18
04:55
Conference/Events
Sirius XM management to meet with B. Riley FBR »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 26

    Nov

04:55
11/15/18
11/15
04:55
11/15/18
04:55
General news
Retail Sales less autos to be reported at 08:30 »

October Retail Sales less…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.